Substrate Specificities and Identification of Putative Substrates of ATM Kinase Family Members*

Ataxia telangiectasia mutated (ATM) phosphorylates p53 protein in response to ionizing radiation, but the complex phenotype of AT cells suggests that it must have other cellular substrates as well. To identify substrates for ATM and the related kinases ATR and DNA-PK, we optimized in vitro kinase assays and developed a rapid peptide screening method to determine general phosphorylation consensus sequences. ATM and ATR require Mn2+, but not DNA ends or Ku proteins, for optimal in vitro activity while DNA-PKCs requires Mg2+, DNA ends, and Ku proteins. From p53 peptide mutagenesis analysis, we found that the sequence S/TQ is a minimal essential requirement for all three kinases. In addition, hydrophobic amino acids and negatively charged amino acids immediately NH2-terminal to serine or threonine are positive determinants and positively charged amino acids in the region are negative determinants for substrate phosphorylation. We determined a general phosphorylation consensus sequence for ATM and identified putative in vitro targets by using glutathioneS-transferase peptides as substrates. Putative ATM in vitro targets include p95/nibrin, Mre11, Brca1, Rad17, PTS, WRN, and ATM (S440) itself. Brca2, phosphatidylinositol 3-kinase, and DNA-5B peptides were phosphorylated specifically by ATR, and DNA Ligase IV is a specific in vitro substrate of DNA-PK.

[1]  C. Wang,et al.  Association of BRCA1 with the hRad50-hMre11-p95 complex and the DNA damage response. , 1999, Science.

[2]  Lei Li,et al.  hRAD17, a structural homolog of the Schizosaccharomyces pombe RAD17 cell cycle checkpoint gene, stimulates p53 accumulation , 1999, Oncogene.

[3]  M. Hill.  Minerva should not review retrospective audits , 1999, BMJ.

[4]  M. Swift,et al.  Link between breast cancer and ATM gene is strong , 1999, BMJ.

[5]  J. Hoeijmakers,et al.  Human and mouse homologs of the Schizosaccharomyces pombe rad17+ cell cycle checkpoint control gene. , 1998, Genomics.

[6]  C. Canman,et al.  The role of ATM in DNA damage responses and cancer , 1998, Oncogene.

[7]  P. Leder,et al.  Loss of atm radiosensitizes multiple p53 null tissues. , 1998, Cancer research.

[8]  P. Jeggo,et al.  Splitting the ATM: distinct repair and checkpoint defects in ataxia-telangiectasia. , 1998, Trends in genetics : TIG.

[9]  X. Shen,et al.  The mammalian Rad24 homologous to yeast Saccharomyces cerevisiae Rad24 and Schizosaccharomyces pombe Rad17 is involved in DNA damage checkpoint. , 1998, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

[10]  F. Alt,et al.  Late embryonic lethality and impaired V (D)J recombination in mice lacking DNA ligase IV , 1998, Nature.

[11]  Y Taya,et al.  Activation of the ATM kinase by ionizing radiation and phosphorylation of p53. , 1998, Science.

[12]  S. Jackson,et al.  DNA repair: The Nijmegen breakage syndrome protein , 1998, Current Biology.

[13]  M. Lavin.  Role of the ataxia-telangiectasia gene (ATM) in breast cancer , 1998, BMJ.

[14]  S. Takashima,et al.  Expression of the ataxia-telangiectasia gene (ATM) product in human cerebellar neurons during development , 1998, Neuroscience Letters.

[15]  R. Darnell,et al.  ATM binds to β-adaptin in cytoplasmic vesicles , 1998 .

[16]  M. Cole,et al.  The Novel ATM-Related Protein TRRAP Is an Essential Cofactor for the c-Myc and E2F Oncoproteins , 1998, Cell.

[17]  S. Jackson,et al.  The DNA-dependent protein kinase , 1999 .

[18]  Y Taya,et al.  DNA damage induces phosphorylation of the amino terminus of p53. , 1997, Genes & development.

[19]  Y. Houvras,et al.  Arrest of the cell cycle by the tumour-suppressor BRCA1 requires the CDK-inhibitor p21WAF1/CiPl , 1997, Nature.

[20]  M. Gatei,et al.  Cellular localisation of the ataxia-telangiectasia (ATM) gene product and discrimination between mutated and normal forms , 1997, Oncogene.

[21]  Y. Shiloh,et al.  Fragments of ATM which have dominant-negative or complementing activity , 1997, Molecular and cellular biology.

[22]  F. Collins,et al.  The ataxia-telangiectasia gene product, a constitutively expressed nuclear protein that is not up-regulated following genome damage. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[23]  A. Carr.  Control of cell cycle arrest by the Mec1sc/Rad3sp DNA structure checkpoint pathway. , 1997, Current opinion in genetics & development.

[24]  Yonghong Xiao,et al.  Association of BRCA1 with Rad51 in Mitotic and Meiotic Cells , 1997, Cell.

[25]  M. Kastan,et al.  p53 and ATM: cell cycle, cell death, and cancer. , 1997, Advances in cancer research.

[26]  Y. Shiloh,et al.  The genetic defect in ataxia-telangiectasia. , 1997, Annual review of immunology.

[27]  Y. Shiloh,et al.  Ataxia-telangiectasia and the Nijmegen breakage syndrome: related disorders but genes apart. , 1997, Annual review of genetics.

[28]  Gang Chen,et al.  The Product of the ATM Gene Is a 370-kDa Nuclear Phosphoprotein* , 1996, The Journal of Biological Chemistry.

[29]  T. Stankovic,et al.  Analysis of the ATM protein in wild-type and ataxia telangiectasia cells. , 1996, Oncogene.

[30]  L. Pinna,et al.  How do protein kinases recognize their substrates? , 1996, Biochimica et biophysica acta.

[31]  S. Schreiber,et al.  PIK-Related Kinases: DNA Repair, Recombination, and Cell Cycle Checkpoints , 1995, Science.

[32]  T. Hunter,et al.  When is a lipid kinase not a lipid kinase? When it is a protein kinase , 1995, Cell.

[33]  V. Zakian.  ATM-related genes: What do they tell us about functions of the human gene? , 1995, Cell.

[34]  K. Khanna,et al.  Nature of G1/S cell cycle checkpoint defect in ataxia-telangiectasia. , 1995, Oncogene.

[35]  M. Skolnick,et al.  BRCA1 mutations in primary breast and ovarian carcinomas. , 1994, Science.

[36]  Steven E. Bayer,et al.  A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. , 1994, Science.

[37]  A. Fornace,et al.  The p53-dependent G1 cell cycle checkpoint pathway and ataxia-telangiectasia. , 1994, Cancer research.

[38]  S. Jackson,et al.  The DNA-dependent protein kinase: Requirement for DNA ends and association with Ku antigen , 1993, Cell.

[39]  B. Vogelstein,et al.  A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia , 1992, Cell.

[40]  K. Sakaguchi,et al.  Human DNA-activated protein kinase phosphorylates serines 15 and 37 in the amino-terminal transactivation domain of human p53 , 1992, Molecular and cellular biology.

[41]  W. Herr,et al.  Ethidium bromide provides a simple tool for identifying genuine DNA-independent protein associations. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[42]  D Morrell,et al.  Incidence of cancer in 161 families affected by ataxia-telangiectasia. , 1991, The New England journal of medicine.

[43]  M. Swift,et al.  Breast and other cancers in families with ataxia-telangiectasia. , 1987, The New England journal of medicine.

[44]  A. Nordheim,et al.  DNA intercalators induce specific release of HMG 14, HMG 17 and other DNA‐binding proteins from chicken erythrocyte chromatin. , 1985, The EMBO journal.